49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

13 trials found

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05339217 (ClinicalTrials.gov)	July 1, 2022	2/4/2022	Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic ...	Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic ...	Systemic Lupus Erythematosus	Drug: Telitacicept;Drug: Interleukin-2	Peking University People's Hospital	NULL	Recruiting	18 Years	65 Years	All	60	Phase 3	China
2	NCT05262686 (ClinicalTrials.gov)	April 1, 2022	22/2/2022	Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2in the Treatment of Systemic Lu ...	Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2in the Treatment of Systemic Lu ...	Systemic Lupus Erythematosus	Drug: Belimumab;Drug: Interleukin-2	Peking University People's Hospital	NULL	Recruiting	18 Years	70 Years	All	10	Phase 3	China
3	NCT04077684 (ClinicalTrials.gov)	September 10, 2019	1/9/2019	Efficacy and Safety of Low-dose IL-2in Patients With SLE: a Multicenter, Randomised, Placebo-control ...	Efficacy and Safety of Low-dose Interleukin-2in Patients With Systemic Lupus Erythematosus: a Multic ...	Systemic Lupus Erythematosus	Drug: Interleukin-2	Peking University People's Hospital	NULL	Recruiting	18 Years	75 Years	All	500	Phase 2	China
4	NCT03312335 (ClinicalTrials.gov)	August 8, 2018	29/9/2017	Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus	Open-label, Monocentric, Phase II, Investigator-initiated Clinical Trial on Unbiased Characterizatio ...	Lupus Erythematosus, Systemic	Drug: Low-dose Aldesleukin (Proleukin®)	Onur Boyman, MD	NULL	Completed	18 Years	N/A	All	16	Phase 2	Switzerland
5	EUCTR2016-000488-17-FR (EUCTR)	16/05/2018	19/03/2019	A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage o ...	A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficac ...	Systematic Lupus Erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Sys ...	Product Name: ILT-101 Product Code: ILT-101 INN or Proposed INN: Aldesleukin Other descriptive name: IN ...	ILTOO PHARMA	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	Portugal;France;Mexico;Spain;Austria;Bulgaria;Italy
6	EUCTR2016-000488-17-BG (EUCTR)	27/03/2017	13/02/2017	A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage o ...	A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficac ...	Systematic Lupus Erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Sys ...	Product Name: ILT-101 Product Code: ILT-101 INN or Proposed INN: Aldesleukin Other descriptive name: IN ...	ILTOO PHARMA	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	Portugal;France;Mexico;Spain;Romania;Austria;Bulgaria;Germany;Italy
7	EUCTR2016-000488-17-ES (EUCTR)	21/11/2016	18/11/2016	A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage o ...	A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficac ...	Systematic Lupus Erythematosus MedDRA version: 19.0;Level: PT;Classification code 10042945;Term: Sys ...	Product Name: ILT-101 Product Code: ILT-101 INN or Proposed INN: Aldesleukin Other descriptive name: IN ...	ILTOO PHARMA	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;Portugal;Mexico;Spain;Austria;Bulgaria;Italy
8	ChiCTR-IPR-16009451	2016-11-01	2016-10-16	The Efficacy and Safety of Low Dose IL-2Conbined Rapamycin Therapy in Chinese Over-treated Patients ...	The Efficacy and Safety of Low Dose IL-2Conbined Rapamycin Therapy in Chinese Over-treated Patients ...	Systemic Lupus Erythematosus	IL-2group:IL-2;IL-2+ Rapamycingroup :IL-2and Rapamycin;non IL-2or IL-6 antagonist group :Glucocortic ...	the Second Hospital of Shanxi Medical University	NULL	Pending	18	80	Both	IL-2 group:20;IL-2 + Rapamycin group :20;non IL-2 or IL-6 antagonist group :20;		China
9	EUCTR2016-000488-17-PT (EUCTR)	24/10/2016	28/07/2016	A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage o ...	A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficac ...	Systematic Lupus Erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Sys ...	Product Name: ILT-101 Product Code: ILT-101 INN or Proposed INN: Aldesleukin Other descriptive name: IN ...	ILTOO PHARMA	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;Portugal;Mexico;Mauritius;Spain;Romania;Austria;Bulgaria;Germany;Italy
10	EUCTR2016-000488-17-AT (EUCTR)	08/08/2016	21/07/2016	A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage o ...	A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficac ...	Systematic Lupus Erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Sys ...	Product Name: ILT-101 Product Code: ILT-101 INN or Proposed INN: Aldesleukin Other descriptive name: IN ...	ILTOO PHARMA	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Portugal;France;Mexico;Mauritius;Spain;Romania;Austria;Bulgaria;Germany;Italy

First Previous1 2Next Last